- 0 Comments
- Breast Cancer
Trastuzumab deruxtecan (Enhertu) followed by paclitaxel, trastuzumab, and pertuzumab (THP) significantly improved pathologic complete response (pCR) compared with standard neoadjuvant chemotherapy in patients with high-risk HER2-positive early-stage breast cancer, according to results from the DESTINY-Breast11 phase III trial. These positive high-level findings mark the first phase III evidence supporting use of trastuzumab deruxtecan to treat […]
Learn More